Magnetic resonance imaging has, over the years, become invaluable for the management of glioma patients. It is commonly used to establish initial diagnostic, target sites for biopsies, plan neuro-surgical resection and to follow-up treatment efficacy. Anatomical protocols such as T1-weighted scans after injection of contrast agents are used to locate areas of leaky blood vessels, which are common in brain tumours. Perfusion, water molecule diffusion and spectroscopy protocols provide additional insight into tumour biology and physiology. Other imaging modalities such as Positron Emission Tomography and Optical Imaging enable the imaging of key molecular processes associated with glioma development, such as proliferation, hypoxia and metabolic activity.

Based on our pre-clinical models of gliomas, we use these imaging modalities to assess the morphological, physiological and metabolic changes that are induced by new treatment modalities, such as anti-angiogenic therapies. Furthermore, we correlate these features with extensive molecular and histological analysis that are relevant in the clinical setting.

Odoo text and image block